IFN-γ1b (human recombinant)

Ligand id: 8341

Name: IFN-γ1b (human recombinant)

No information available.
Summary of Clinical Use
IFN-γ1b is approved to treat chronic granulomatous disease (CGD) [3] and severe, malignant osteopetrosis [2]. In 2007, the EMA granted orphan designation for the use of interferon gamma to treat idiopathic pulmonary fibrosis. The product also has EMA and FDA orphan designation for the treatment of Friedreich’s ataxia [4]..
Mechanism Of Action and Pharmacodynamic Effects
IFN-γ1b activates interferon receptors and induces expression of genes with antiviral, antibacterial, antiapoptotic, antitumor, and immunomodulatory effects [1,5]. The molecular mechanism underlying the clinical benefit of IFN-γ1b therapy is poorly understood.